Daewon Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Daewon Pharmaceutical has a total shareholder equity of ₩289.7B and total debt of ₩184.9B, which brings its debt-to-equity ratio to 63.8%. Its total assets and total liabilities are ₩598.7B and ₩309.0B respectively. Daewon Pharmaceutical's EBIT is ₩31.1B making its interest coverage ratio 4.4. It has cash and short-term investments of ₩71.8B.
Key information
63.8%
Debt to equity ratio
₩184.89b
Debt
| Interest coverage ratio | 4.4x |
| Cash | ₩71.78b |
| Equity | ₩289.71b |
| Total liabilities | ₩308.98b |
| Total assets | ₩598.69b |
Recent financial health updates
Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Aug 13
Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Mar 26Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly
Dec 10
Recent updates
Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) P/E Still Appears To Be Reasonable
Jan 06Daewon Pharmaceutical's (KRX:003220) Conservative Accounting Might Explain Soft Earnings
Nov 22Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Aug 13Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors
Jul 17There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings
Mar 21Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Mar 26Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?
Mar 07Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?
Feb 18Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Jan 31Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?
Jan 13Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend
Dec 24Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly
Dec 10Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?
Nov 22Financial Position Analysis
Short Term Liabilities: A003220's short term assets (₩264.2B) exceed its short term liabilities (₩208.8B).
Long Term Liabilities: A003220's short term assets (₩264.2B) exceed its long term liabilities (₩100.2B).
Debt to Equity History and Analysis
Debt Level: A003220's net debt to equity ratio (39%) is considered satisfactory.
Reducing Debt: A003220's debt to equity ratio has increased from 23.9% to 63.8% over the past 5 years.
Debt Coverage: A003220's debt is not well covered by operating cash flow (13%).
Interest Coverage: A003220's interest payments on its debt are well covered by EBIT (4.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 23:37 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Daewon Pharmaceutical Co., Ltd. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. |
| Jae Hoon Shin | Hanwha Investment & Securities Co., Ltd. |
| Changhee Woo | IBK Securities Co. Ltd. |